Age, Biography and Wiki

Michel Alary was born on 13 July, 1954 in Canada, is a Canadian academic, doctor. Discover Michel Alary's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 69 years old?

Popular As N/A
Occupation Doctor, academic and health researcher
Age 69 years old
Zodiac Sign Cancer
Born 13 July 1954
Birthday 13 July
Birthplace Canada
Nationality Canada

We recommend you to check the complete list of Famous People born on 13 July. He is a member of famous doctor with the age 69 years old group.

Michel Alary Height, Weight & Measurements

At 69 years old, Michel Alary height not available right now. We will update Michel Alary's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.

Physical Status
Height Not Available
Weight Not Available
Body Measurements Not Available
Eye Color Not Available
Hair Color Not Available

Dating & Relationship status

He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.

Family
Parents Not Available
Wife Not Available
Sibling Not Available
Children Not Available

Michel Alary Net Worth

His net worth has been growing significantly in 2023-2024. So, how much is Michel Alary worth at the age of 69 years old? Michel Alary’s income source is mostly from being a successful doctor. He is from Canada. We have estimated Michel Alary's net worth, money, salary, income, and assets.

Net Worth in 2024 $1 Million - $5 Million
Salary in 2024 Under Review
Net Worth in 2023 Pending
Salary in 2023 Under Review
House Not Available
Cars Not Available
Source of Income doctor

Michel Alary Social Network

Instagram
Linkedin
Twitter
Facebook
Wikipedia
Imdb

Timeline

1954

Michel Alary (born July 13, 1954) is a Canadian academic, doctor of preventive medicine and a health researcher.

He is a Professor of Social and Preventive Medicine at Université Laval and the director of population health research at the Research Centre of the CHU de Quebec – Université Laval.

He also serves as a Medical Consultant at the Institut national de santé publique du Québec.

Alary has published over 260 research papers and has produced major reports for the World Bank and UNAIDS about HIV in sub-Saharan Africa.

He also evaluated the Bill & Melinda Gates Foundation's India AIDS Initiative for which his project received the Avahan Recognition Award.

He has conducted epidemiological and preventive research on blood-borne infections, HIV and other Sexually Transmitted Diseases (STD) among the most vulnerable populations in developed and developing countries.

Alary is the recipient of Mark Wainberg Lecturer Award from the Canadian Association for HIV Research, Researcher Emeritus Award from the Réseau de la recherche ne santé des populations du Québec and the Graduate Emeritus award from the Fondation de l’Université laval.

He has also served as President of the International Society for STD Research.

Alary is a Fellow of the Canadian Academy of Health Sciences and a founding member of the Canadian Association for HIV Research (CAHR).

1970

Alary received his Diploma of College Studies in 1970, Doctorate in Medicine in 1974, and License from the Medical Council of Canada in 1975, from Université de Sherbrooke.

1975

Alary started his career as a family physician in various institutions from 1975 till 1983.

1986

He joined Université Laval in 1986 as a teaching assistant and a lecturer in the Department of Social and Preventive Medicine.

1987

He then engaged in general practice of family medicine before receiving his Masters and Doctorate degrees in Epidemiology from Université Laval in 1987 and 1991, respectively.

1990

His research in the early 1990s indicated that amoxycillin was an appropriate treatment for genital infections caused by Chlamydia trachomatis in pregnant women.

He compared amoxicillin and erythromycin in a double blinded and randomized study.

The results from the experiment led to the inclusion of amoxicillin as one of the recommended treatments for Chlamydia trachomatis as whereas cure rates were similar in both groups when treatment was completed, there were more women stopping their treatment with erythromycin because of side effects.

Form the mid 1990s till now, Alary led a longitudinal study about HIV and HCV prevalence and incidence among people who inject drugs (PWID) in the province of Quebec.

His work has been used extensively by Quebec's health authorities and community groups involved in HIV prevention among PWID.

1991

After receiving a Fellowship from the National Health Research and Development Program and from the Fonds de la Recherche en Santé du Québec, Alary moved to Belgium and was associated with Institute of Tropical Medicine as a Post-doctoral fellow from 1991 till 1992.

During his post-doctoral fellowship at Institute of Tropical Medicine from 1991 till 1992, Alary performed an epidemiological study on HIV infection in European female sex workers (FSWs) and presented population data to show that the use of petroleum-based lubricants was associated with a higher prevalence of HIV infection.

His research outcomes led to the reinforcement of prevention programs aimed at FSWs in Europe regarding the promotion of water-based lubricants.

During his Fellowship, he also conducted research on the STI-HIV interaction and the low and middle-income countries (LMICs).

His research indicated that other STDs increase the risk of HIV sexual transmission, and that HIV incidence can be decreased by controlling the STDs.

1992

He was promoted to assistant professor in 1992, to associate professor in 1996 and to professor in 2000.

Alary has served as a medical advisor at Hôpital du Saint-Sacrement, Centre de santé publique de Québec, Institut national de santé publique du Québec and Ministère de la santé et des services sociaux du Québec.

He also has considerable experience in international health projects.

Along with his academic positions, Alary has also held several administrative appointments.

1996

From 1996 to 2003, Alary led the Omega Cohort Study on HIV infection in men who have sex with men (MSM) in Montreal.

This study made a significant contribution in the field of participatory research.

Indeed, the implication of the MSM community in all aspects of this study helped to form the basis for the development of the community-based HIV research program at the Canadian Institutes of Health Research.

During his tenure as an assistant professor at Laval University, Alary focused on clinical manifestations of non-ulcerative STIs, especially in women.

His work led to the development of the syndromic approach for the diagnosis and treatment of STIs in developing countries.

He was involved in the development of the World Health Organization guidelines that recommended the use of this approach in LMICs.

He applied the criteria of sensitivity and specificity to evaluate a screening algorithm regarding STD's in female sex workers.

His research highlighted the constraints in the screening of STD in developing countries.

1998

He directed the Epidemiology Research Group of Université Laval from 1998 till 2000 and then served as a Director of STD/AIDS Scientific Group at Institut national de santé publique du Québec till 2001.

He is the director of population health research at the Research Centre of the CHU de Quebec – Université Laval.

Alary is an External Scholar at Dalhousie University in Nova Scotia.

Alary's research is focused primarily on HIV and STD prevention.

He has conducted epidemiologic and prevention research on blood-borne infections and STDs among the most vulnerable populations in both developing and developed countries.